Utility of $S_{\text{UV}}\text{max}$ on $^{18}$F-FDG PET in detecting cervical nodal metastases

Rebecca S. M. Lim$^{1,2,6}$*, Shakher Ramdave$^3$, Paul Beech$^{3,4}$, Baki Billah$^5$, Md Nazmul Karim$^5$, Julian A. Smith$^2$, Adnan Safdar$^{1,2}$ and Elizabeth Sigston$^{1,2}$

Abstract

**Background:** The presence of cervical lymph node metastasis is an important prognostic factor for patients with head and neck squamous cell carcinomas (HNSCC). Accurate assessment of lymph node metastasis in these patients is essential for appropriate prognostic and management purposes. Here, we evaluated the effectiveness of the maximum standardized uptake value ($S_{\text{UV}}\text{max}$) on positron emission tomography (PET) in assessing lymph node metastasis in HNSCC prior to surgery.

**Methods:** A retrospective review of 74 patients with HNSCC who underwent PET/CT prior to neck dissection were examined. Pre-operative PET/CT scans were reviewed by two experienced nuclear medicine physicians and $S_{\text{UV}}\text{max}$ of the largest node in each nodal basin documented. These were compared with the histology results of the neck dissection.

**Results:** A total of 359 nodal basins including 86 basins with metastatic nodes were evaluated. A nodal $S_{\text{UV}}\text{max} \geq 3.16$ yielded a sensitivity of 74.4 % and specificity of 84.9 % in detecting metastatic nodes. The nodal $S_{\text{UV}}\text{max}$/Liver $S_{\text{UV}}\text{max}$ ratio was found on receiver operating characteristic (ROC) to be effective in detecting metastatic nodes with an area under ROC curve of 0.90. A nodal $S_{\text{UV}}\text{max}$/Liver $S_{\text{UV}}\text{max}$ ratio $\geq 0.90$ yielded a sensitivity of 74.1 % and specificity of 93.4 %. By comparison, visual inspection yielded sensitivities of 66.3 and 61.6 % in observers 1 and 2 respectively. The corresponding specificities were 77.7 and 86.5 %.

**Conclusions:** Nodal $S_{\text{UV}}\text{max}$ and nodal $S_{\text{UV}}\text{max}$/liver $S_{\text{UV}}\text{max}$ are both useful in the pre-operative detection of metastatic nodes with the latter being superior to visual inspection. The ratio is likely to be more useful as it corrects for inter-scanner variability.

**Keywords:** Lymphadenopathy, Metastasis, Positron emission tomography (PET), Standardized uptake value, Squamous cell carcinoma

**Background**

Accurate nodal staging of the neck is essential in guiding management and predicting prognosis for patients with head and neck squamous cell carcinoma (HNSCC). A single nodal metastasis reduces a patient’s survival rate by 50 %—this is further halved with bilateral lymphadenopathy [1–3]. The use of $^{18}$F-fluorodeoxyglucose positron emission tomography ($^{18}$F-FDG PET) in the workup of HNSCC has allowed non-invasive, quantitative assessment of a tissue by analysing the 3-dimensional distribution of radioactivity based on the annihilation photons that are emitted by labelled tracer [4]. PET scans are superior to computed tomography (CT) and magnetic resonance imaging (MRI) because metabolic changes resulting from malignancies precede structural changes [5]. However, while providing metabolic information about tissues, PET scans offer poor visualization of anatomic structures, thereby limiting their use. This shortcoming has been overcome by integrated $^{18}$F-FDG PET/CT scanners and has improved the nodal staging of the neck [6, 7].

At present, there have been only two studies that have examined the relationship between the maximum standardized uptake value ($S_{\text{UV}}\text{max}$) of a node and the...
presence of nodal metastasis [8, 9]. Both studies used nodal $SUV_{\text{max}}$ in conjunction with nodal size measured from the CT images to predict nodal metastasis. There have been no studies using nodal $SUV_{\text{max}}$ alone or using a ratio nodal $SUV_{\text{max}}$ and background tissue $SUV_{\text{max}}$ to negate variables that could cause different $SUV_{\text{max}}$ readings between patients and between institutions.

The aims of this study were to define a nodal $SUV_{\text{max}}$ cut-off with the greatest sensitivity and specificity for the detection of nodal metastasis, as well as to determine if a ratio between nodal $SUV_{\text{max}}$ and each of aortic blood pool $SUV_{\text{max}}$, liver $SUV_{\text{max}}$ and primary tumour $SUV_{\text{max}}$ could be used as a universal predictor of cervical lymph node metastasis.

Methods

Study population

This retrospective single tertiary centre study identified 74 patients from January 2011 to December 2014 with newly diagnosed HNSCC who had undergone elective neck dissection with curative intent at the Department of Otolaryngology and Head & Neck Surgery, Monash Health, Melbourne.

The exclusion criteria included the following: patients who had previous chemotherapy or radiotherapy for any malignancy; patients who did not undergo pre-operative $^{18}$F-FDG PET/CT or had $^{18}$F-FDG PET/CT scans performed external to our institution; patients whose neck dissection specimens were not clearly divided into the individual levels; and patients who did not have a HNSCC, were excluded. The study protocol was approved by the ethics committee at Monash Health.

PET/CT imaging and SUV measurements

$^{18}$F-FDG PET/CT scans were obtained with an advanced integrated PET/CT scanner (Siemens Biograph™ TruePoint™). All patients were fasted for at least six hours prior to the PET/CT examination. A standard dose of 300 MBq $^{18}$F-FDG tracer was used for all patients. In the period between injection of $^{18}$F-FDG tracer and image acquisition, the patient was instructed to remain seated or recumbent and silent in order to minimize muscular $^{18}$F-FDG uptake. Patients were kept warm 30–60 min prior to tracer injection and throughout the uptake period in order to minimize $^{18}$F-FDG accumulation in brown fat. Blood glucose was measured for all diabetic patients to ensure that it was within acceptable limits. Patients with blood glucose >10 mmol/L were rescheduled. Image acquisition was performed 53 to 124 min after tracer injection. Dual time point imaging was not used in this study.

A standard scan for suspected HNSCC at our institution covered vertex to upper thighs. The CT images were acquired without contrast and comprised of a tomodogram and the helical CT scan. The reconstruction parameters used for a standard scan were 168matrix, True D reconstruction, FWHM 5.0, 3 iterations, 21 subsets and 1.0 zoom.

After the acquisition, $SUV_{\text{max}}$ was assessed on the Siemens syngo MultiModality WorkPlace (MMWP) system by a single nuclear medicine physician. $SUV_{\text{max}}$ was determined by manually placing a cylindrical region of interest (ROI) over the largest lymph node in each nodal basin of interest, as well as the primary tumour site, the descending aorta and liver. This was done on trans-axial images by an experienced nuclear medicine physician. Node $SUV_{\text{max}}$ values were divided by the $SUV_{\text{max}}$ of the primary tumour, descending aorta and liver to calculate the following:

- nodal $SUV_{\text{max}}$/primary tumour $SUV_{\text{max}}$
- nodal $SUV_{\text{max}}$/aortic $SUV_{\text{max}}$
- nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$

The short and long axis of the largest node in each nodal basin were also recorded.

Only cervical nodal levels 1 to 5 were examined in this study as these were the most common levels removed in a neck dissection.

Two nuclear medicine physicians then systematically examined each PET/CT scan visually and determined which cervical nodal levels had metastatic nodes. This was compared to the pathology results. A nodal basin with at least one metastatic node was deemed to be a ‘metastatic basin’, regardless of the number of metastatic nodes within the basin or the size of the metastatic deposit(s).

Histopathological analysis

Neck dissection specimens were either removed level by level or en bloc and then divided into the individual nodal levels. Nodal evaluation was performed by dedicated head and neck pathologists at our institution, in accordance with the guidelines issued by the Royal College of Pathologists in the United Kingdom. The specimens were inspected and palpated and each discrete palpable node was dissected out with attached peri-capsular adipose tissue. These nodes were then placed in a cassette which was then stained and serially sliced prior to being loaded onto pathology slides for viewing under the microscope. Pathologic findings on the lymph nodes were recorded at each anatomic level. Only lymph nodes in cervical levels one to five were examined— intra-parotid, occipital or pre-auricular nodes were excluded.

The pathology reports were reviewed by the investigators to determine if the nodal basin contained any metastatic nodes.
All statistical analyses were performed using IBM SPSS version 22 by two bio-statisticians. The pathologic status and SUV\(_{\text{max}}\) of cervical lymph nodes were collected for calculating the receiver operating characteristic (ROC) curve and Youden's Index for determining the cut-off value for SUV\(_{\text{max}}\). The Youden index, which is a comprehensive measurement for the performance of a diagnostic test, was generated considering every possible cut-off point. The value that generates the highest Youden's Index for the particular ratio is considered as the best cut-off for that ratio, as it provides highest discrimination between pathology and no pathology. A \(p\)-value of 0.05 or less was considered statistically significant.

Binary logistic regression was applied to assess the association of individual predictor with chance of metastasis adjusting for all possible confounding. For choosing the most suitable predictor for metastatic node a backward logistic regression was fitted including all plausible predictors. \(p < 0.05\) was considered as significant.

### Statistical analysis

All statistical analyses were performed using IBM SPSS version 22 by two bio-statisticians. The pathologic status and SUV\(_{\text{max}}\) of cervical lymph nodes were collected for calculating the receiver operating characteristic (ROC) curve and Youden's Index for determining the cut-off value for SUV\(_{\text{max}}\). The Youden index, which is a comprehensive measurement for the performance of a diagnostic test, was generated considering every possible cut-off point. The value that generates the highest Youden's Index for the particular ratio is considered as the best cut-off for that ratio, as it provides highest discrimination between pathology and no pathology. A \(p\)-value of 0.05 or less was considered statistically significant.

### Results

#### Patient demographics

The study cohort consisted of 74 patients with HNSCC, including 57 males and 17 females. The median patient age was 64 (range 35–89). Primary sites included the oral cavity, hypopharynx, larynx and skin. Five patients had no primary site found (Table 1).

#### Type of neck dissection

A total of 95 neck-sides, including 359 nodal basins, were dissected (Table 2). Metastatic nodes were found in 86 of 359 levels (24.0 %). The most common neck dissection performed was a selective neck dissection of levels I to IV (33.7 %) followed by a selective neck dissection of levels II to IV (21.1 %), supra-omohyoid neck dissection of levels I to III (SOHND) (17.9 %) modified radical neck dissection of levels I to V (MRND) (13.7 %), selective neck dissection of levels II to V (8.4 %) and radical neck dissection of levels I to V (5.3 %).

### SUV\(_{\text{max}}\) for pathologically positive and negative lymph nodes and the cut-off value for diagnosis

SUV\(_{\text{max}}\) was measured for the largest lymph node in each level and compared with the results of histopathologic examination. The median SUV\(_{\text{max}}\) values of pathologically negative and positive nodes were 1.55 (range 0.58–5.2) and 5 (range 0.91–23.49) respectively. The median primary tumour SUV\(_{\text{max}}\) was 14.26 (range 3.89–36.69). The median aortic SUV\(_{\text{max}}\) was 2.70 (range 1.79–4.68). The median liver SUV\(_{\text{max}}\) was 3.38 (range 2.27–5.51).

A Receiver Operating Characteristic (ROC) curve was drawn and the Youden's Index used to determine the cut-off value for SUV\(_{\text{max}}\) at which sensitivity and specificity were the highest (Table 3). The best nodal SUV\(_{\text{max}}\) cut-off was found to be 3.16. This yielded a sensitivity of 74.4 % and specificity of 84.9 %.

### SUV\(_{\text{max}}\) ratios for pathologically positive and negative lymph nodes and the cut-off value for diagnosis

A ROC analysis was employed to evaluate usefulness of three different ratios in determining the presence or absence of metastatic nodes:

- nodal SUV\(_{\text{max}}\)/primary tumour SUV\(_{\text{max}}\)
- nodal SUV\(_{\text{max}}\)/aortic SUV\(_{\text{max}}\)
- nodal SUV\(_{\text{max}}\)/liver SUV\(_{\text{max}}\)

The results are shown in Fig. 1 and Table 4. ROC analysis of Nodal SUV\(_{\text{max}}\)/Primary SUV\(_{\text{max}}\) ratio, Nodal SUV\(_{\text{max}}\)/Aorta SUV\(_{\text{max}}\) ratio and Nodal SUV\(_{\text{max}}\)/Liver SUV\(_{\text{max}}\) ratio confirms that the latter two ratios are good predictors of nodal metastasis (Fig. 1). Nodal SUV\(_{\text{max}}\)/Primary SUV\(_{\text{max}}\) ratio was a poorer predictor than the other two ratios. To choose the best predictor

### Table 1 Primary Sites

| Primary site | Frequency | Percent |
|-------------|-----------|---------|
| Oral cavity | 43        | 58.1    |
| Larynx      | 13        | 17.6    |
| Cutaneous   | 10        | 13.5    |
| UNPHNC      | 5         | 6.8     |
| Hypopharynx | 3         | 4.1     |
| Total       | 74        | 100     |

### Table 2 Nodal Basins Dissected

| Nodal basin | Dissection frequency | No. of positive basins | % of tumours ipsilateral to the positive node | % of tumours contralateral to the positive node | % of tumours midline to the positive node | % of positive nodes with unknown primaries |
|-------------|----------------------|------------------------|---------------------------------------------|-----------------------------------------------|------------------------------------------|-------------------------------------------|
| Level I     | 70                   | 18                     | 10/18 (55.6 %)                              | 1/18 (5.6 %)                                  | 3/18 (16.7 %)                            | 4/18 (22.2 %)                             |
| Level II    | 95                   | 33                     | 18/33 (54.5 %)                              | 3/33 (9.1 %)                                  | 5/33 (15.1 %)                            | 7/33 (21.2 %)                             |
| Level III   | 95                   | 21                     | 12/21 (57.1 %)                              | 1/21 (4.8 %)                                  | 6/21 (28.3 %)                            | 2/21 (9.5 %)                              |
| Level IV    | 77                   | 10                     | 6/10 (60.0 %)                               | 0/10 (0 %)                                    | 3/10 (30.0 %)                            | 1/10 (10.0 %)                             |
| Level V     | 27                   | 4                      | 2/4 (50.0 %)                                | 0/4 (0 %)                                     | 2/4 (50.0 %)                             | 0/4 (0 %)                                 |
| Total       | 364                  | 86                     | 48/86 (55.8 %)                              | 5/86 (5.8 %)                                  | 19/86 (22.1 %)                           | 14/86 (16.3 %)                            |
of nodal metastasis adjusting for all possible confounding factors a stepwise backward elimination multivariable logistic regression analysis was performed on all the potential PET predictors of nodal metastasis. After each step, the predictor with the lowest $p$-value was removed. By the end of the analysis, nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$ ratio was found to be the best predictor for nodal metastasis (Table 4).

The optimal cut-off value for nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$ ratio is 0.903. This means that a node with a nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$ of greater than or equal to 0.903 is considered metastatic with a sensitivity of 74.1% and specificity of 93.4% (Table 5).

**Comparing visual detection of metastatic nodes, nodal SUV$_{\text{max}}$ and nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$**

ROC analysis of visual detection of metastatic nodes, nodal SUV$_{\text{max}}$ and nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$ ratio found that while visual detection demonstrated good discrimination between metastatic and benign nodes, the use of nodal SUV$_{\text{max}}$ and nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$ had better discrimination. The area under the curves for visual observer 1 was 0.737 and 0.703 for visual observer 2. In contrast, the area under the curve was 0.883 for both nodal SUV$_{\text{max}}$ and nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$ (Table 6 and Fig. 2). Observer 1 detected metastatic nodes with a sensitivity of 66.3% and a specificity of 77.7%, while the corresponding values for Observer 2 were 61.6 and 86.5%. Using a Nodal SUV$_{\text{max}}$/Liver SUV$_{\text{max}}$ ratio of $>$0.903 yielded a sensitivity of 72.8% and specificity of 93.8%.

**Short and long nodal diameters had no statistically significant impact on predicting nodal basin metastasis**

The short and long axis of the largest node in each nodal basin were recorded. Neither diameter was a statistically significant predictor of a metastatic basin (Table 7).

**Multi-variable analysis of various indicators of metastatic nodes**

Multivariable logistic regression was conducted with plausible indicators of metastatic nodes. Adjusting for all possible confounders and indicators entered in the model nodal SUV$_{\text{max}}$ appeared as significant indicator of metastatic nodes. (OR 3.275; 95%CI: 2.018–5.317; $P<0.000$). None of the other factors ‘primary tumour SUV$_{\text{max}}$’ ($p>0.05$), ‘extra-capsular spread’ ($p>0.05$), ‘nodal necrosis’ ($p>0.05$), largest nodal diameter ($p>0.05$) and smallest nodal diameter ($p>0.05$) appeared to be significant indicators of metastatic nodes (Table 8).
Discussion

The introduction of $^{18}$F-FDG PET/CT has greatly improved preoperative staging of HNSCC. As the presence of nodal metastasis is one of the most important prognostic factors for patients with HNSCC, accurate nodal staging of these patients is essential for both appropriate management and prognostic purposes [2, 7, 10].

For malignancies with a high risk of occult nodal metastasis, such as oral cavity SCC, elective neck dissections are routinely performed on patients with clinically negative necks. This serves staging as well as therapeutic purposes. However, for patients in whom an elective dissection is not planned based on the site and histological grade of the primary tumour, nodal staging is based solely on clinical examination and radiological imaging. In these cases, the use of SUV$_{\text{max}}$ can aid in distinguishing between metastatic and benign nodes, and thus in deciding whether an elective neck dissection should be undertaken.

The standardized uptake value (SUV) is the most widely used method for the quantification of $^{18}$F-FDG uptake [11]. The SUV of a target can be expressed as SUV$_{\text{mean}}$ or SUV$_{\text{max}}$. SUV$_{\text{mean}}$ is the average SUV calculated from multiple voxels, while SUV$_{\text{max}}$ is the highest voxel SUV reading in the region of interest. [12] The SUV$_{\text{max}}$ is the more common method of reporting SUV, due to the fact that it is more reproducible and less observer-dependent than SUV$_{\text{mean}}$ [12, 13]. The SUV$_{\text{max}}$ is used at our institution for this reason. In our study, we have also decided to perform a per-nodal-level analysis as this analysis is commonly presented in the literature and allows comparison with other studies.

The use of SUV$_{\text{max}}$ to detect nodal metastases has been studied extensively in lung cancers, but not in head and neck malignancies. A study by Bryant et al. included 397 patients with non-small cell lung cancer and found that the median SUV$_{\text{max}}$ of metastatic mediastinal lymph nodes was significantly higher than that of benign nodes. Indeed, when a SUV$_{\text{max}}$ cutoff of 5.3 was used instead of the traditional value of 2.5, the accuracy of $^{18}$F-FDG-PET/CT for detecting mediastinal lymph node metastasis increased to 92 % [14]. Another study by Ela Bella et al. looked at the ideal SUV$_{\text{max}}$ cutoff for identification of metastatic mediastinal lymph nodes and found SUV$_{\text{max}}$ of 4.1 to be ideal. This cut-off yielded a sensitivity of 80 % and specificity of 92 % [15]. A similar SUV$_{\text{max}}$ cut-off for identifying metastatic mediastinal lymph nodes was reported by Vansteenkiste et al. [16].

The use of SUV$_{\text{max}}$ to detect nodal metastases in the head and neck has only been reported in two studies. In 2012, Matsubara et al. looked at 38 patients with oral SCC and compared their pre-operative $^{18}$F-FDG-PET/CT scan results with histopathological findings [8]. The authors reported that nodes with a SUV$_{\text{max}}$ of more than 4.5 were all pathologically confirmed as being metastatic, but for nodes with SUV$_{\text{max}}$ ≤ 4.5, it was not possible to distinguish between true positives and false positives. Hence, the long and short axis diameters were measured for those nodes and the long-axis diameter was found to be significantly longer in the true positive nodes. No significant difference between the true positive and false positive nodes were found in the short-axis diameter.

Murakami et al. studied 23 patients with HNSCC and found that SUV$_{\text{max}}$ accurately characterized lymph nodes >15 mm in diameter, but was not reliable with respect to nodes <15 mm. Thus, size based SUV$_{\text{max}}$ cutoffs were used in this study: they were 1.9 for nodes less than 10 mm in diameter, 2.5 for those 10 – 15 mm, and 3.0 for nodes more than 15 mm. These values yielded 79 % sensitivity and 99 % specificity [9].

The limitations of these studies are the small sample sizes and the lack of accounting for other variables that could influence SUV readings. These include the blood sugar level of the patient at the time of PET scanning, the presence of an inflammatory process near the tumour, patient movement and the interval between injection of $^{18}$F-FDG and acquisition of PET.

In our study, we have found that nodal SUV$_{\text{max}}$ was a statistically significant predictor of metastatic nodes (p < 0.001), and that a nodal SUV$_{\text{max}}$ cut-off of ≥3.16 yielded a sensitivity of 74.4 % and specificity of 84.9 %.

Table 4: Stepwise multi-variable logistic regression analysis

| Predictor          | B      | S.E.  | P Value | OR   | 95 % CI. for OR |
|--------------------|--------|-------|---------|------|----------------|
| Nodal SUV$_{\text{max}}$/Liver SUV$_{\text{max}}$ | 4.114  | 0.556 | .000*  | 61.1 | 20.2 – 185.6   |
| Constant           | -4.642 | 0.496 | .000    | 0.010|                |

*Statistically significant

Table 5: Optimal nodal SUV$_{\text{max}}$/liver SUV$_{\text{max}}$ ratio for generating cut-off with maximum sensitivity and specificity

| Nodal SUV$_{\text{max}}$/Liver SUV$_{\text{max}}$ ratio | Highest Youden’s Index | Cut-off | Sensitivity | Specificity | Likelihood Ratio Pos. Test | Likelihood Ratio Neg. Test |
|--------------------------------------------------------|------------------------|---------|-------------|-------------|---------------------------|---------------------------|
| 0.675                                                   | 0.903                  | 0.741   | 0.934       | 11.266      | 0.277                     |                           |

Positive if greater Than or Equal To
then hypothesized that a ratio of $SUV_{\text{max}}$ values (ie, nodal $SUV_{\text{max}}$/background $SUV_{\text{max}}$) may be one way to negate these inherent differences between PET centres and standardize the measurement. Thus we measured the $SUV_{\text{max}}$ of the liver parenchyma, aortic blood pool and primary tumour to see if these ratios could improve the detection of metastatic nodes. Multi-variable logistic regression analysis found the nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$ ratio to be able to distinguish, with statistical significance, between metastatic and benign nodes. This ratio offered a similar sensitivity as nodal $SUV_{\text{max}}$ alone (74.1 % compared to 74.4 %). The significance of our results are that the nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$ is able to negate inherent differences between patients and PET centres and therefore standardize the measurement.

This is the first study to propose using a SUV ratio to detect metastatic cervical nodes. Currently, the lack of literature on this matter means that arbitrary $SUV_{\text{max}}$ cut-off values are used. These vary significantly between institutions and the evidence for their use is lacking. Using the nodal $SUV_{\text{max}}$ cut-off and/or the $SUV_{\text{max}}$ ratio cut-off proposed in this study, in addition to the usual methods of detecting a nodal metastasis, might improve the overall sensitivity and specificity of PET/CT for the detection of metastatic nodes.

Improving the pre-operative detection of nodal metastasis is important as it has the potential to alter surgical management. In patients for whom an elective dissection is not planned based on the site and histological grade of the primary tumour, nodal staging is based mainly on clinical examination and radiological imaging. In these cases, the use of nodal $SUV_{\text{max}}$ alone or nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$ can aid in distinguishing between metastatic and benign nodes, and thus in deciding whether an elective neck dissection should be undertaken.

Using a nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$ ratio also allows comparison of nodal tracer uptake between PET scans performed using different scanners. Currently, a comparison is not meaningful due to differences in scanner calibration and thus SUV readings. However, a ratio would negate inherent differences between scanners, making it possible to compare a pre-treatment PET scan with a post-treatment PET scan performed at a different centre to assess treatment response.

While we think the use of nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$ ratio is promising, there are a few caveats in the use of

| Table 6 Receiver operating characteristics of visual detection and nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$ ratio |
|--------------------------------------------------|
| Observer 1 | Sensitivity | 61.63 | Specificity | 86.45 | PPV | 58.89 | NPV | 87.73 | AUC (95 % CI) | 0.703 (0.633, 0.772) |
| Observer 2 | Sensitivity | 66.28 | Specificity | 77.66 | PPV | 48.31 | NPV | 87.97 | AUC (95 % CI) | 0.737 (0.667, 0.807) |
| N/L SUV ($\geq 0.903$) | Sensitivity | 72.84 | Specificity | 93.78 | PPV | 81.94 | NPV | 89.91 | AUC (95 % CI) | 0.883 (0.772, 0.894) |

Fig. 2 ROC curves of visual detection, and nodal $SUV_{\text{max}}$/liver $SUV_{\text{max}}$ ratio
liver SUV as a proxy for background $SUV_{max}$. The first is that the liver has an abundance of glucose-6-phosphatase, which could cause continuous glycolysis and reduce its measured SUV more rapidly compared to other tissues. However, a prospective study by Laffon et al. performed PET acquisition at two time points on the same day and reported that the decay-corrected SUV of the liver remains nearly constant if the time delay between tracer injection and PET acquisition is in the range of 50–110 min. [17] This suggests that in clinical practice, liver SUV can be used for comparison with SUV of suspected malignant lesions, if comparison is made within this timeframe.

Another caveat of using liver SUV is in the presence of fatty liver. This has been suggested to result in a slightly decreased metabolic activity [18], while another study reported no significant difference in SUV max [19]. The presence of liver tumours or metastatic disease would also give spurious liver SUV readings [20].

The main drawback of using nodal SUV max is that this measurement might be spuriously low in necrotic nodes. In these cases, correlation with CT findings is essential.

Another limitation of this study is the time lapse between the PET/CT scan and surgery. The median time between a patient in our study having the PET/CT scan and the neck dissection was 27 days (range 1–62). Disease progression could have occurred during this time and what was initially a benign node at the time of scanning could have turned malignant by the time of surgery.

Despite these limitations, our study has shown nodal SUV max and nodal SUV max/liver SUV max ratio to be better detectors of metastatic nodes than visual inspection. This is surprising as visual interpretation integrates more information than the nodal SUV max or SUV max ratio measurements, in particular the distribution pattern, size, number and relative intensity of lesions and the relationship of the lesions with the primary tumour, to determine the probability of these foci of uptake representing metastatic disease. A meta-analysis by Sun et al. published in 2015 included 19 studies that performed a per-nodal-level analysis and found that the pooled sensitivity and specificity was 80 % (range 0 %–96.3 %) and 96 % (range 73.4 %–98.9 %) respectively [21]. We acknowledge that our sensitivities and specificities for visual inspection were somewhat lower than this but when a Nodal SUV max/Liver SUV max ratio of >0.903 was used the sensitivity and specificity yielded was comparable.

A few reasons may account for the difference. Firstly, selective reporting bias may have contributed to the high reported sensitivities and specificities of $^{18}$FDG-PET/CT in the meta-analysis. Furthermore, 12 of the 19 studies that were included in the meta-analysis had either CT and/or MRI performed in addition to the $^{18}$FDG-PET/CT. Thus, it is possible that the imaging observers might have known the diagnostic outcome of other conventional imaging methods before assessing the results of $^{18}$FDG-PET/CT imaging, resulting in a spuriously high sensitivity and specificity for $^{18}$FDG-PET/CT.

**Conclusions**

This preliminary study has identified two predictors of metastatic nodes on PET scans—nodal SUV max and nodal SUV max/liver SUV max ratio. It is the first study examining the utility of a SUV ratio in detection of metastatic cervical lymph nodes and more data are needed from a larger number of patients from multiple centres. Further research could examine prospectively if these predictors, combined with conventional visual detection methods, are able to improve the overall accuracy of detecting metastatic cervical lymph nodes.

**Abbreviations**

$^{18}$F-FDG: 18F-fluorodeoxyglucose; HNSCC: Head and neck squamous cell carcinoma; MRND: Modified radical neck dissection; PET: Positron emission tomography; ROC: Receiver operating characteristic; SCC: Squamous cell carcinoma; SUV: Standardized uptake value

**Acknowledgements**

Mr. Jason Bradley, Charge Technologist of Nuclear Medicine and PET (Monash Imaging), who kindly helped with the technical retrieval of PET/CT scans for viewing by our nuclear medicine physicians and with the technical aspects of the PET scanning protocol.

**Funding**

Statistical analysis funded by Monash University Department of Surgery. Monash University played no role in the actual design of the study and collection.

**Availability of data and materials**

Please contact author for data requests.
Authors’ contributions

RSL, MBBS (Hons). Study design, data collection and writing of manuscript. SR, MBBS, MD, FRACP. Study design, data collection, interpretation of PET scans, reviewing of manuscript. PB, MBBS, FRANZCR, FAANMS. Data collection, interpretation of PET scans. BB, BSc (Hons), MAs, PhD. Statistical analysis. MdNK MSc, MBBS. Statistical analysis. JAS, MBBS, MS, FRACS. Supervised the study design, and facilitated data collection and reviewed manuscript. AS, MBBS, FRCS, FRACS. Supervised the study design and facilitated data collection and reviewed manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study protocol was approved by the ethics committee at Monash Health on 12th March 2014 (Research Project application No. 14073Q).

Author details

1. Department of Otolaryngology and Head & Neck Surgery, Monash Medical Centre, 823-865 Centre Rd, Bentleigh East, VIC 3165, Australia. 2. Department of Surgery, School of Clinical Sciences, Monash University, 246 Clayton Rd, Clayton, VIC 3168, Australia. 3. Department of Nuclear Medicine & PET, Monash Medical Centre, 823-865 Centre Rd, Bentleigh East, VIC 3165, Australia. 4. Department of Nuclear Medicine, The Alfred, First Floor, East Block, Commercial Road, Melbourne, VIC 3004, Australia. 5. Department of Public Health, Monash University, The Alfred Centre, 99 Commercial Road, Melbourne, VIC 3004, Australia. 6. Department of Radiology, Westmead Hospital, Cnr Hawkesbury Road and Darcy Road, Westmead, NSW 2145, Australia.

Received: 25 November 2015 Accepted: 25 October 2016

Published online: 08 November 2016

References

1. Mukherji SK, Armstrong D, Joshi VM. Cervical nodal metastases in squamous cell carcinoma of the head and neck: what to expect. Head Neck. 2001;23(1):195–1005.
2. Nguyen A, Luginihi A, Cognetti D, Van Abel K, Bar-Ad V, Intenso C, et al. Effectiveness of PET/CT in the preoperative evaluation of neck disease. Laryngoscope. 2014;124(1):159–64.
3. Walden MJ, Aygun N. Head and neck cancer. Semin Oncol. 2013;40(1):35–46.
4. Boelard R, Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200.
5. Mylly K, Castaigne C, Flamen P. 18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer. Curr Opin Oncol. 2005;17(3):249–53.
6. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008;100(10):712–20.
7. Yongkui L, Jian L, Wanghan, Jingui L. 18FDG-PET/CT for the detection of regional nodal metastasis in patients with primary head and neck cancer before treatment: a meta-analysis. Surg Oncol. 2013;22(2):11–6.
8. Matsubara R, Kawano S, Chikui T, Kiyosue T, Goto Y, Hirano M, et al. Clinical significance of combined assessment of the maximum standardized uptake value of F-18 FDG PET with nodal size in the diagnosis of cervical lymph node metastasis of oral squamous cell carcinoma. Acad Radiol. 2012;19(6):708–17.
9. Murakami R, Uozumi H, Hirai T, Nishimura R, Shiishi S, Ota K, et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2007;68(2):377–82.
10. Agarwal V, Branstetter BF, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin N Am. 2008;41(1):23–49. v.
11. Siddiqui F, Faulhaber PF, Yao M, Le Q-T. The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma. PET Clinics. 2012;7(4):381–94.
12. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195(2):310–20.
13. Lee JR, Madsen MT, Bushnel D, Menda Y. A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun. 2000;21(7):685–90.
14. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg. 2008;82(2):417–22, discussion 22–3.
15. Ela Bella AJ, Zhang YR, Fan W, Luo KJ, Rong TH, Lin P, et al. Maximum standardized uptake value on PET/CT in preoperative assessment of lymph node metastasis from thoracic esophageal squamous cell carcinoma. Chin J Cancer. 2014;33(4):211–7.
16. Vansteenwijk JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16(6):2142–9.
17. Laffon E, Adhoute X, de Clermont H, Marthan R. Is liver SUV stable over time in (1)F-FDG PET imaging? J Nucl Med Technol. 2011;39(4):258–63.
18. Qazi F, Oliver D, Nguyen N, Osman M, Fatty Iver: Impact on metabolic activity as detected with 18F FDG-PET/CT. J Nucl Med. Meeting Abstracts. 2008;49(MeetingAbstracts_1):263P–C.
19. Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology. 2010;254(3):917–24.
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:1225–505.
21. Sun R, Tang X, Yang Y, Zhang C. (18)FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis. Oral Oncol. 2015;51(4):314–20.